Latest News – Page 2 – Safe Biologics

In Shocking Reversal, CMS Wants to Allow Medicare Part D Plan Sponsors to Substitute Non-Interchangeable Biosimilars

November 12, 2023

On November 6, 2023, the Centers for Medicare and Medicaid Services (CMS) announced a proposed Rule that would permit Medicare Part D plan sponsors to substitute non-interchangeable biosimilars in place of the biologic medicines now used to treat many chronic conditions such as rheumatoid arthritis, Crohn’s disease and cancer. The policy change represents a stark […]

ASBM Letter to Congress Defends Interchangeability Standard

September 27, 2023

In a letter to Senator Mike Lee (R-UT) dated September 27th, ASBM urged the Senator to reconsider his support for S.6 “The Biosimilar Red Tape Elimination Act”, which would prevent the HHS Secretary from requiring switching studies in order for a biosimilar to be deemed “interchangeable”. Under U.S. state law, only interchangeable biosimilars are substitutable at the […]

Medicare Price “Negotiations” Will Jeopardize Patient Access to New Medicines, Result in Worse Health Outcomes

September 11, 2023

September 11, 2023 The Centers for Medicare & Medicaid Services (CMS) recently announced the first 10 drugs selected under its Medicare drug price “negotiation” plan, authorized by the Inflation Reduction Act (IRA) signed in to law last year. Over the next 4 years, Medicare will set prices for up to 60 drugs covered under Medicare […]

ASBM Experts Discuss Interchangeable Biosimilars on AI Arthritis Podcast

September 6, 2023

On September 6th, AI Arthritis released Episode 88 of its AI Arthritis 360 Talk Show, in which ASBM representatives discuss potential policy changes regarding interchangeable biosimilars and how they may undermine the patient protections currently in place. Joining AI Arthritis Executive Director and host Tiffany Westrich-Robertson were ASBM Executive Director Michael Reilly, ASBM Chairman Ralph McKibbin MD […]

Dr. McKibbin Presents Poster Session at DIA Global Annual Meeting 2023

July 20, 2023

On June 26th, ASBM Chairman Ralph McKibbin presented a poster at the DIA Global Annual Meeting in Boston, MA. The poster was based on the findings from ASBM’s Canadian ophthalmologist survey and compared the findings with those of other physicians surveyed in recent years. The surveys examined physician attitudes toward biosimilar substitution practices, pharmacovigilance and nomenclature standards, and different […]

ASBM & GaBI Host Webinar on IRA Medicare Price Negotiations Impact on Innovation, Patient Access

July 13, 2023

On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines which focused on unintended consequences for patient access that may result from the implementation of the Inflation Reduction Act (IRA). The webinar focused on the IRA’s price negotiation […]

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development

June 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Mr. Spiegel is a founding member of ASBM and Executive Director of the Global Colon Cancer Association. In the op-ed, Spiegel highlights the importance of small-molecule drugs in cancer therapy, and notes […]

ASBM’s Michael Reilly Participates in IFA’s Vision Health Month Webinar

May 15, 2023

On May 15th, ASBM Executive Director Michael Reilly participated in a webinar entitled Impact of Emerging Policies on the Vision of Older Canadians hosted by the International Federation on Ageing (IFA). As part of the celebration of the Vision Health Month, this webinar was executed to raise awareness on the importance of eye health, prevention of vision […]

GaBI Journal Publishes ASBM/IFA Canadian Ophthalmologist Survey Findings

May 10, 2023

On May 9th, GaBI Journal published a whitepaper titled “Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars”, based on the recent survey of 41 Canadian ophthalmologists by ASBM and the International Federation on Ageing (IFA). The paper is authored by IFA Secretary-General Jane Barratt and ASBM Executive Director Michael Reilly. The survey revealed that 81% were not […]

GaBI Journal publishes Whitepaper on Canadian Ophthalmologist Survey

May 9, 2023

On May 9th, GaBI Journal published a whitepaper titled “Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars”, based on the recent survey of 41 Canadian ophthalmologists by ASBM and the International Federation on Ageing (IFA). The paper is authored by IFA Secretary-General Jane Barratt and ASBM Executive Director Michael Reilly. The survey revealed that 81% […]